Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characteristics and Outcomes of Adolescents (15-18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML.

Cancers·2026

Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026

Same author

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

The Lancet. Haematology·2026

Same author

Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults.

HemaSphere·2026

Same author

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Leukemia·2025

Same author

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients.

Cancer immunology, immunotherapy : CII·2025

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Immunotherapy in chronic myelogenous leukemia.

François Guilhot¹, Lydia Roy, Geraldine Martineua

¹Department of Oncology-Hematology and Cell Therapy, Clinical Research Centre, Centre Hospitalier Universitaire de Poitiers, France.

Clinical Lymphoma & Myeloma

|March 27, 2007

Summary

Immunotherapy shows promise for chronic myelogenous leukemia (CML). Combining interferon with imatinib and exploring vaccine strategies may improve molecular responses and prevent relapse, though leukemic stem cells persist.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Experiment Videos

Last Updated: Jul 16, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Area of Science:

Hematology
Immunology
Oncology

Background:

Chronic myelogenous leukemia (CML) is a leukemic disorder responsive to immunotherapy.
Interferon-based regimens were the first to achieve complete cytogenetic responses in CML.
Imatinib is now standard first-line therapy, but may not eradicate leukemic stem cells.

Purpose of the Study:

To describe current immunotherapeutic strategies for chronic myelogenous leukemia.
To highlight the potential of combining imatinib with interferon for enhanced molecular responses.
To discuss the role of allogeneic stem cell transplantation and vaccine strategies in CML treatment.

Main Methods:

Review of existing literature on immunotherapy in CML.
Discussion of ongoing phase III trials combining interferon and imatinib.
Overview of phase II trials investigating Bcr-Abl junction oligopeptide vaccines.
Consideration of allogeneic stem cell transplantation and graft-versus-host disease.

Main Results:

Interferon-based regimens achieved complete cytogenetic responses.
Combination therapy with interferon and imatinib is being explored in phase III trials.
Vaccine strategies show a good safety profile in patients with complete cytogenetic and molecular responses.
Allogeneic stem cell transplantation is associated with fewer relapses in patients experiencing graft-versus-host disease.

Conclusions:

Immunotherapy remains a critical area of investigation for chronic myelogenous leukemia.
Combination therapies and novel vaccine strategies offer potential for improved outcomes.
Despite advances, eradicating leukemic stem cells remains a challenge, necessitating continued research in immunotherapy.